. 2017 Dec 19;9(2):2268–2278. doi: 10.18632/oncotarget.23405

Table 1. IC50 of anticancer drugs in Reh cells and resistant cells.

Drugs	IC50 (μg/mL)			^aRelative resistance	^bRelative resistance
Drugs	Reh	Reh-6MPR	Reh-6TGR	^aRelative resistance	^bRelative resistance
6-MP	0.18±0.02	174.23±16.75^***	125.73±3.54^***	968	699
6-TG	0.09±0.01	104.50±2.79^***	86.05±5.82^***	1161	956
MTX	0.005±0.0006	0.0039±0.0001	0.004±0.0002	0.78	0.80
AraC	0.0024±0.0001	0.0018±0.0002	0.0016±0.0001	0.75	0.67

Values are given as mean ± SD. IC50 of resistant cells to 6-MP and 6-TG differed significantly from Reh cells, ^***P<0.001 compared with Reh group. ^aRelative resistance was obtained by dividing the IC50 mean value of Reh cells by the IC50 value of Reh-6MPR cells; ^bRelative resistance was obtained by dividing the IC50 mean value of Reh cells by the IC50 value of Reh-6TGR cells.